APM - Aptorum Group Ltd
Previous close
1.04
0.155 14.894%
Share volume: 104
Last Updated: Fri 27 Dec 2024 08:24:30 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$0.89
0.15
17.50%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
17.24%
1 Month
21.65%
3 Months
-53.51%
6 Months
-81.42%
1 Year
-66.27%
2 Year
-82.80%
Key data
Stock price
$1.04
DAY RANGE
$0.88 - $0.89
52 WEEK RANGE
$0.71 - $17.49
52 WEEK CHANGE
-$64.87
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Darren Lui
Region: US
Website: www.aptorumgroup.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: www.aptorumgroup.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Aptorum Group Limited engages in the discovery, development, and commercialization of therapeutic products. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas.
Recent news